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Natural products are increasingly being considered ‘‘critical and important’’ in drug discovery
paradigms as a number of them such as camptothecin, penicillin, and vincristine serve as ‘‘lead
molecules’’ for the discovery of potent compounds of therapeutic interests namely irinotecan,
penicillin G, vinblastine respectively. Derived compounds of pharmacological interests dis-
played a wide variety of activity viz. anticancer, anti-inﬂammatory, antimicrobial, anti-proto-
zoal, etc.; when modiﬁcations or derivatizations are performed on a parent moiety
representing the corresponding derivatives. Pyridoacridine is such a moiety which forms the
basic structure of numerous medicinally important natural products such as, but not limited
to, amphimedine, ascididemin, eilatin, and sampangine. Interestingly, synthetic analogues of
natural pyridoacridine exhibit diverse pharmacological activities and in view of these, natural
pyridoacridines can be considered as ‘‘lead compounds’’. This review additionally provides a
brief but critical account of inherent structure activity relationships among various subclasses
of pyridoacridines. Furthermore, the current aspects and future prospects of natural pyridoac-
ridines are detailed for further reference and consideration.
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The pivotal role of natural products in novel drug discovery
programme can be ascertained from the fact that approximately
40% of Food and Drug Administration, USA (FDA) approved
therapeutic drugs have natural origin [1]. The drugs derived via
taking ‘‘lead’’ from nature, have shown immense potential in
terms of their chemical diversity and biosynthetic molecular rec-
ognition usually absent in synthetically developed libraries. A
‘‘lead compound’’ can be deﬁned as a compound responsible
for synthesis of a series of compounds via chemical modiﬁca-
tions in order to achieve optimal therapeutic activity [2]. A num-
ber of drugs derived from the natural sources are available in the
market for different ailments (Table 1). In general, a lead com-
pound is identiﬁed on the basis of its ability to bind to a thera-
peutic target. Once designated as a ‘‘tight-binder’’, this leadTable 1 Different medicinally important natural lead compounds a
S. no. Lead compounds Derived drugs
1 Camptothecin Irinotecan, Topotecan
2 Paclitaxel Docetaxel
3 Vincristine Vinblastine, Vindesine, Vinorelbine
4 Etoposide Teniposide
5 Quinine Quinidine
6 Digitoxin Digoxigenin
7 Cephalosporin C Ceﬁxime, Cefuroxime
8 Morphine Codeine, Pholcodeine, Ethylmorphi
9 Artemisinin Artesunate, Artemether
10 Penicillin G Penicillin X
11 Tetracycline Chlortetracyclins, Oxytetracyclins
12 Atropine Hyoscine
13 Ergotamine Ergotoxin, Ergometrine
14 Theophylline Choline theophyllinate
15 Dopamine Levodopa, Carbidopacompound can be chemically modiﬁed to improve the target
speciﬁcity, bioavailability, and pharmacokinetics and ﬁnally
tested for their therapeutic activity via pre-clinical and clinical
studies [2].
Pyridoacridines, a class of marine-derived alkaloids charac-
terized by a 11H-pyrido[4,3,2-mn]acridine, fulﬁl all the require-
ments of being lead compounds in their respective therapeutic
category [32]. With varied chemical compositions and confor-
mations differing by (1) different side chains; (2) rings fused to
ring C; (3) rings fused to the acridine nitrogen; (4) bromination
at C2 in ring A; and (5) varied oxidation states, pyridoacri-
dines present an array of biological activities with respect to,
but not limited to, anticancer, anti-HIV, antimicrobial, anti-
parasitic, anti-viral and insecticidal activities [33]. Further-
more, pyridoacridines are also associated with calcium ions
release from sarcoplasmic reticulum, neuronal differentiation,
metal chelation, and depict afﬁnity towards GABA receptors
[34]. Various subclasses of pyridoacridines such as amphime-
dines, ascididemins, petrosamines, dercitins, diplamines, and
eilatins provide important chemical cues and clues to act as
lead compounds (Fig. 1). For example, various pyridoacridines
displayed their anticancer activities via different mechanism
like binding with DNA, inhibition of DNA/RNA/protein syn-
thesis, inhibition of topoisomerase, cleavage/catenation/dam-
age of DNA, cell cycle arrest and hence can be employed as
‘‘hits’’ in further lead optimization [32–34].
Although some comprehensive reviews are available on
pyridoacridines such as Molinski’s one [32] which describes
the structure, synthesis and biological chemistry of pyridoacri-
dines or the other by Marshall and Barrows [34], which
reviewed the biological activities of pyridoacridines; the pres-
ent review describes a correlation between various important
structural aspects of pyridoacridines with respect to their bio-
logical activities demonstrating their potential as lead com-
pounds for the future [32,34].
Different natural pyridoacridines are shown in Fig. 1.
Inspired by these natural pyridoacridines, researchers around
the world are synthesizing medicinally active derivatives. In
view of the above mentioned facts, pyridoacridines can be con-
sidered as ‘‘Prospective lead compounds’’ of the future. The
word ‘‘Prospective lead compounds’’ can be exempliﬁed from
the different representative examples of pyridoacridine deriva-nd their derived drugs.
Medicinal Importance References
Anticancer [3,4]
Anticancer [5,6]
Anticancer [7,8]
Anticancer, Cytotoxic [8,9]
Antimalarial, Antiarrythmic [10,11]
In Cardiovascular diseases [12,13]
Antimicrobial [14,15]
ne Antitussives; Analgesic [16,17]
Antimalarial [18,19]
Antimicrobial [20,21]
Antimicrobial [22,23]
Anticholinergic [24,25]
a-adrenergic blockers, Uterine stimulants [26,27]
Bronchodilators [28,29]
Parkinsonism [30,31]
Shermilamine B Styelsamine BLabuanin A Dercitamine Eudistone
Diplamine PetrosaminePlakinidine D Cystodytin A Lissoclin B
Cystodimine BEilatin PantherinineSampangine
Ascididemin DercitinCalliactine Arnoamine A
Amphimedine Kuanoniamine ANeoamphimedine Deoxyamphimedine Meridine
Fig. 1 Natural pyridoacridines.
A mini review on pyridoacridines 65tives to be covered in coming sections. In addition, structural
activity relationship points may further prove their candida-
ture as lead compounds for different ailments. Furthermore,
for the interest of the readers, due care has been taken as the
present review limit itself to discussion on different analogues
of representative natural pyridoacridines with promising
activities only and discussion has been provided with sub-
heads namely: amphimedine analogues, ascididemin ana-
logues, dercitin analogues, eilatin analogues, kuanoniamine
analogues, sampangine analogues and current/future
prospects.
Scope of the review
This review primarily focuses on the representative publica-
tions of last 20 years (i.e. from 1994 to 2014) related tochemical and medicinal aspects of pyridoacridines; each repre-
senting a unique study about pyridoacridine analogues.
Search terms like pyridoacridine, pyridoacridine derivative,
lead, amphimedine, ascididemin, kuanoniamine, sampangine,
dercitin, eilatin were used to ﬁnd out different publications
on natural as well as synthetic analogues of pyridoacridines
by using various E-resources and databases like Google Scho-
lar, American Chemical Society, Wiley-Blackwell Publishing,
Elsevier Science, Nature, Royal Society of Chemistry, Springer
Link, Taylor and Francis, Pubmed Scopus, Reaxys, Bielstein
and Sciﬁnder.
Amphimedine analogues
A small difference in the structure of a drug may impose notice-
able effect on its pharmacological activity like three natural
66 V. Sharma et al.analogues of amphimedines namely: amphimedine, neoam-
phimedine, deoxyamphimedine bear only small differences in
structures but neoamphimedine and deoxyamphimedine both
possess antitumour activity. On the other hand, the study
describes amphimedine as relatively inactive (Fig. 1). As per a
study performed by Marshall and co-workers [35], neoam-
phimedine antitumour activity equals to well-known anticancer
agent etoposide while in reference to work by Matsumoto et al.
[36], authors speculate that mechanism behind anticancer activ-
ity of deoxyamphimedine could be redox cycling and reactive
oxygen species (ROS) generation emanated from its iminoqui-
none moiety [35–37]. Authors further concluded that being a
positively charged compound; deoxyamphimedine demon-
strated signiﬁcantly different biological activities as compared
to neoamphimedine and deoxyamphimedine.
Ponder et al. [38], demonstrated the inﬂuence of carbonyl
group position in biological activity with the help of molecular
docking studies. Docking studies on ATPase site of TopoIIa
enzyme revealed that carbonyl group of neoamphimedine
interacts with Ser-148 residue at ATPase but in case of
amphimedine, hydrogen bonding with Ser-148 was lost which
resulted in unfavourable steric interaction with the active site
Mg2+ and ultimately loss of biological activity [38].
Different analogues of amphimedine were synthesized via
Diels–Alder reaction and their cytotoxic potential was assessed
on human cancer cell lines with varying histopathological
types (colon, lung, glioblastomas and bladder cancers) by
using MTT assay. Interestingly, it was reported that most
similar analogues of amphimedine i.e. compound 1 and
compound 2 were found to exhibit highest cytotoxic potential
with IC50 value less than 10
7 M [39].
Ascididemin analogues
Marshall and co-workers [40] discussed structure activity rela-
tionship among different analogues of ascididemin i.e. AK37
and AK36 (Fig. 2). Structurally, the only difference between
ascididemin and AK37 is the presence of an additional N-atom
in ascididemin; while mechanistically AK37 act by inhibiting
the catalytic activity of both topo I/II and stabilizes the
DNA-Topo I cleavable complex. The DNA-Topo I cleavable
complex stabilizing function of AK37, the ﬁrst pyridoacridineN
N
N
O
B C D
E
A
N
O
A
Ascididemin A
N
N
O
A B C D
E
F N
O
O
AK36
Fig. 2 The basic structure of ascto show this activity, as compared to the ROS-generating func-
tion of ascididemin, can be attributed to the absence of nitro-
gen in the ‘A’ ring of AK37. However, complete removal of
ring ‘D’ from AK37 maintained the DNA-Topo I cleavable
complex stabilization in BC21 which proves that ring ‘D’ does
not exhibit any important role in AK37’s Topo I activity. In
case of AK36, the presence of an additional ring ‘F’ prevented
DNA intercalation by AK36 and rendered it lower cytotoxicity
than the related compounds. Additionally, the presence of ring
‘F’ in AK36 diminished the DNA-Topo I cleavable complex
stabilizing functions observed in AK37 [40].
In a study, Lindsay et al. [41], provided the structure activ-
ity relationship of various ascididemin analogues. In brief, the
authors assessed the importance of ring A and ring E of
ascididemin (Fig. 2) by synthesizing different analogues of
ascididemin and carried out a range of assays for the evalua-
tion of their biological activity. Presence of nitrogen in ring
A is essential for the inhibition of Escherichia coli and
Cladosporium resinae while its absence results in Trichophyton
mentagrophytes inhibition. [41]. Alternatively, dramatic
increase in antitumour/antifungal/antibacterial activity was
evaluated by the presence or absence of ring E in ascididemin
and compound 3 respectively (Fig. 2). Furthermore, it was
concluded that ascididemin acts through multiple mechanisms
towards mammalian cell systems [41]. Similar to these studies,
Appleton and co-workers synthesized ring A analogues of
ascididemin containing furan and thiophene rings which
showed considerable antitubercular activity [42].
In their study, Guittat et al. [43], determined the afﬁnity of
ascididemin for DNA quadruplexes and ﬁndings of the study
indicated that large ﬂat aromatic surface of ascididemin might
be responsible for their binding with DNA quadruplexes. Fur-
thermore, authors asserted that presence of positive charge on
nitrogen atom of ascididemin would enhance, as DNA quad-
ruplex has high negative charge density [43].
Delfourne and co-workers [44], further suggested that the
cytotoxic activity of the ascididemin isomer (compound 4)
can be retained even after manipulating positions 5 and 7 on
ring D [44].
In a study conducted by Delfourne and co-workers in [45],
ascididemin analogues were synthesized and evaluated for
their cytotoxic potential by MTT assay. Some ascidideminN
D
N
N
O
A
K37 BC21
N
3
ididemin and their analogues.
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than the reference compound ascididemin (Table 2). Further-
more, it was reported that substitution at R1 and R3 does
not have much inﬂuence on cytotoxic activity [45].
Debnath and co-workers [46], carried out QSAR studies on
the above mentioned ascididemin analogues reported by
Delfourne et al. [45] and emphasized that the presence of an
electron withdrawing substituent with higher molar refractivity
value and the presence of NHR (R is hydrogen or alkyl group)
at R1 and R3 positions, respectively, favoured the anti-tumour
activity of ascididemin analogues [Fig. 3] [45,46].
In this period of shortage of antitubercular drugs; Appleton
and co-workers [42], synthesized and evaluated a series of asci-
didemin analogues and found thioethyl analogue i.e. compound
17 to exhibit potent antitubercular activity againstMycobacte-
rium tuberculosis ((Mtb) H37Rv) strain (IC50 = 0.34 lM) as
compared to reference compound rifampin (IC50 = 0.152 lM)
[42]. Encouraged by these observations, authors made the
following assertions:Fig. 3 Pharmacophoric atoms and required physicochemical propert
for their anti-tumour activity ([46], Reproduced with permission from
Table 2 Ascididemin derivatives along with mean IC50 of 12 differe
and MCF7); three glioblastomas (SW1088; U-373 MG and U-87 MG
cell lung (A549; A-427) cancer cell lines.
N
N
N
O
Compound R1 R2
5 NH2 H
6 H Br
7 H NH2
8 H NHCH2CH2C
9 H N(CH2CH2Cl
10 H NHCH2CH2N
11 H Cl
12 H CH3
13 H OCH3
14 H N(CH3)2
15 H NHBn
16 H NH2
Ascididemin H H1. ‘‘Size-reduced analogues of ascididemin may provide a useful
scaffold for future studies.’’
2. Iminoquinone moiety of ascididemin is essential for antitu-
bercular activity.
Dercitin analogues
In 1992, Taraporewal and co-workers studied the anti-HIV
and anti-tumour activities of dercitin analogues. Dercitin
(Fig. 1), a pyridoacridine obtained from Dercitus sp. sponge
namely Dercitus simplex, Dercitus lististinus [47], exerts its
cytotoxic effect on mammalian cells through four basic nitro-
gen atoms capable of binding to the acidic amino acid residues.
Furthermore, progressive removal of these basic nitrogen
atoms results in lowering of cytotoxic potential of dercitin.
In addition to nitrogen atoms, the presence of a fused thiazole
ring contributed to the cytotoxic activity of dercitin while theies of substituents at R1 and R3 positions of ascididemin analogues
Elsevier B.V. Ltd.ª 2003).
nt cell lines viz., two colon (HCT-15; LoVo); two breast (T-47D
); one prostate (PC-3); two bladder (J82; T24) and two non small-
R2
R1
R3
R3 Mean IC50 (nM)
H 53
H 80
H 21
l H 7
)2 H 100
(CH3)2 H 60
H 270
H 60
H 90
H 37
H 140
Br 140
H 100
NS
N
N
NMe2
B C D
E
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S
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O
R
Dercitin 18: R=H
19: R=cyclopropyl
HN
N
N
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N
N
N
N
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niﬁcant beneﬁt. Compounds 18 and 19 possessed best anti-
HIV activity. The presence of a sulphur atom seemed to be
essential for antiviral activity of dercitin analogues while the
acidic carboxylic group decreases viral afﬁnity towards lym-
phocytes. Similarly, the occurrence of a mercaptoacetic acid
group at the C-2 position in compounds 18 and 19 on the
tricyclic ABC acridine nucleus demonstrated highest HIV-1
neutralization activity along with the partial inhibition of viral
afﬁnity towards lymphocytes [48].
Eilatin analogues
Eilatin (Fig. 1) is a highly symmetrical heptacyclic alkaloid iso-
lated in 1988 from the red sea tunicate Eudistoma sp. A new
family of eilatin-containing metal complexes is under investi-
gation for their unusual nucleic acid binding speciﬁcity [49].
In a similar study, Zeglis and Barton [50], investigated the
DNA-binding properties of Ru(bpy)2(eilatin)
2+ (compound
20) to determine speciﬁcity of sterically expansive eilatin ligand
for DNA [50]. From the results it was concluded that extended
planar surface presented by eilatin is responsible for its speci-
ﬁcity and anti-HIV activity [49,51].X
Y
N
N
O
1: Y=N
2: X=N
N N
N
O
5
7
4
N
N
O
S
17
20Kuanoniamine analogues
Different pentacyclic analogues of kuanoniamine A (Fig. 1)
were synthesized for their antiprotozoal activity against viru-
lent strains i.e. Leishmania donovani; Leishmania major and
Toxoplasma gondii. As reported, most of the synthesized com-
pounds were found to be more active than well-known drugs
pentamidine, pyrimethamine, sulfadiazine and spiramycin
against T. gondii. On the other hand, compound 21 and com-
pound 22 displayed an IC50 of 6 nM against L. major as com-
pared to reference compound pentamidine (IC50 = 1.8 nM).
Authors neither discussed any structure activity relationship
points nor they proposed any mechanism behind antiprotozoal
activity. Although lipophilicity was mentioned as an important
factor behind antiprotozoal activity while the presence of boc
group and quinoneimine function might be responsible for anti-
protozoal activity [52,53].
Sampangine analogues
A series of sampangine analogues were synthesized and
screened for their antitubercular activity by Claes and co-
workers [54]. As reported, most of the compounds showed
promising activity against M. tuberculosis ((Mtb) H37Rv)
strain of tuberculosis and minimal inhibitory concentrations
(MIC) were measured for most potent sampangine derivative
i.e. compound 23 as low as 0.39 lM [54].
In another study, sampangine analogues were synthesized
to evaluate their antimicrobial activity and to investigate the
role of azaquinoid partial structure in the pharmacological
activity. The microbial strains selected were namely Pseudomo-
nas aeruginosa, E. coli, Staphylococcus aureus, Candida albicans
and Aspergillus niger. In this study, authors concluded that
presence of amino group in compound 24 and compound 25
NN
S
O
O
NHBoc
N
O
O
NHBoc
N
N
O
21 22 23
N N
H
N
N N
N
N S
N
OO
24 25 26
A mini review on pyridoacridines 69while presence of sulphone moiety in compound 26 might be
responsible for their signiﬁcant antimicrobial activity [55].
In order to convert hit into lead, and lead into drug candi-
date it is very important to study their structural activity rela-
tionships; so that characteristic aspects like the nature of
functional group, bulkiness of the molecule, electronegative
effect, and inductive effect caused by the presence of a moi-
ety/group, etc. should be considered. After discussing the rep-
resentative pyridoacridine analogues and their important
structure activity relationship (SAR) points, it can now be
easily concluded that the ‘‘pyridoacridine moiety’’ will be
helpful to design new medicinally active molecules and in view
of these assertions, pyridoacridines can be designated as ‘‘lead
compounds’’.
Current status and future prospects
The literature discloses the biological potential of naturally
available pyridoacridines, and the total synthesis of almost
every natural pyridoacridine is available [32–34]. With the help
of these available procedures, nowadays it is easy for medicinal
chemists to prepare analogues of pyridoacridines in order to
improve their biological activity and to lay down some
interesting structure–activity relationship points for future
research. Currently, search is in progress to identify novel bio-
logically active pyridoacridine analogues on the basis of struc-
ture–activity relationship, such as, Marshall and co-workers
[40], claimed AK37 as the ﬁrst pyridoacridine reported to inhi-
bit the catalytic activity of both topoisomerase I/II and stabi-
lize the DNA-topo I cleavable complex [40]. Furthermore, in a
similar study on pyridoacridine analogues, Delfourne and
coworkers reported that some of the synthesized analogues
are more cytotoxic than the reference compound ascididemin
while Nukoolkarn et al. [56] opinionated that the quaternary
ammonium group plays an important role in acetylcholinester-
ase inhibitory activity of ascididemin [56]. On the other hand,
Guittat and co-workers identiﬁed quaternary ammonium
group responsible for high afﬁnity towards DNA quadruplex,
due to high negative charge density present on DNA quadru-
plex [43].
Pyridoacridines were also found to possess biological activ-
ity equivalent to some well-known biologically active agents.
For example, neoamphimedine showed anticancer activityequivalent to etoposide when tested in mice bearing human
epidermoid-nasopharyngeal tumour cell line. Similarly neoam-
phimedine responds to HCT-116 tumours as effectively as in
case of 9-aminocamptothecin, an anticancer drug in clinical
development [35,57].
Because of continued interest in pyridoacridine analogues,
a new class of ‘‘pyridoacridine-metal complexes’’ (like
Ru(bpy)2(eilatin)
2+) was discovered where due to planar
surface presented by the eilatin, afﬁnity towards nucleic acid
binding improves [51].
Heterocyclic derivatives are well known for their biological
potential [58,59] and similarly heterocyclic-pyridoacridine ana-
logues were reported by some researchers in their studies. For
example Appleton and coworkers, in their study published in
2010 reported furan and thiophene analogues of ascididemin
with signiﬁcant antitubercular activity [42] while in case of
non-heterocyclic analogues like thioethyl analogue, which dis-
played considerable antitubercular activity and authors
pointed out that this analogue could be considered as a useful
scaffold for future studies [42]. The search is underway in some
cases where the pyridoacridine analogues were synthesized but
their biological activity and mechanism of action remain to be
explored, for example synthesis of ascididemin analogues by
Plodek and co-workers [60]; preparation of pyridoacridine
analogues by Godard and co-workers [61]; and synthesis of
sampangine derivatives by Vasilevsky and co-workers [62],
etc. Looking at the promising results, the research in this area
could provide some useful drugs of future.
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